Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/avB6 Bispecfic ADC JSKN022
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin avB6, for the treatment of advanced malignant solid tumors. JSKN022 is the […]